

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.

NOV-0001

In Re Application Of: Chen

NOV 18 2003

Serial No.

10/072,823

Filing Date

2/8/2002

Examiner

Meller

Group Art Unit

1654

Title: ANTI-CANCER AGENTS AND METHODS OF USE THEREOF

Address to:

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
NOV-0001

In Re Application: Chen

Serial No.
10/072,823

Filing Date
2/8/2002

Examiner
Meller

Group Art Unit
1654

ANTI-CANCER AGENTS AND METHODS OF USE THEREOF

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **06-1130**
as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on **11/14/2003** with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Rebecca L. Blake
Signature of Person Mailing Correspondence

Rebecca L. Blake

Typed or Printed Name of Person Mailing Certificate

***This certificate may only be used if paying by deposit account.**

J. Michael Buchanan
Signature

J. Michael Buchanan

Registration No. 44,571

Customer No. 23413

Telephone No. 860-286-2929

Dated: November 14, 2003

CC:

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) NOV-0001		Application Number 10/072,823	
		Applicant(s) Sophie Chen		Filing Date 2/8/2002	
		Group Art Unit 1654			
*EXAMINER INITIAL		OTHER DOCUMENTS <i>(Including Author's File, Date, Pertinent Pages, Etc.)</i>			
		Sophie Chen, "In Vitro Mechanism of PC SPES", Urology (2001) 58(Supplement 2A) 28-35			
		William K. Oh et al., "Activity of the Herbal Combination, PC-SPES, in the Treatment of Patients with Adrogen-Independent Prostate Cancer, Urology (2001) 57(1): 122-126			
		Hank Porterfield, "UsToo PC-SPES Surveys: Review of Studies and Update of Previous Survey Results", Molecular Urology, Volume 4, Number 3, 2000, pp. 289-291			
		B. L. Pfeifer et al., "PC-SPES, A Dietary Supplement for the Treatment of Hormone-Refractory Prostate Cancer", BJU International (2000), 85, 481-485			
		Eric J. Small et al., "Prospective Trial of the Herbal Supplement PC-SPES in Patients with Progressive Prostate Cancer", Journal of Clinical Oncology, Vol. 18, No. 21 (November 1), 2000: pp. 3595-3603			
		Ikezoe et al., "Oridonin Induces Growth Inhibition and Apoptosis of a Variety of Human Cancer Cells", Int. J. Oncol.23: 1187-1193, 2003			
EXAMINER		DATE CONSIDERED			

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.